| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3932 |
| Trial ID | NCT06486051 |
| Disease | Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma | Primary Mediastinal Large B-Cell Lymphoma | Non-Hodgkin's Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | WZTL-002 CAR T-cells |
| Phase | Phase2 |
| Recruitment status | Not Recruiting |
| Title | A Phase 2 Trial to Evaluate the Efficacy and Safety of WZTL-002 in Patients With Relapsed or Refractory Large B-cell Lymphoma (ENABLE-2) |
| Year | 2024 |
| Country | New Zealand |
| Company sponsor | Malaghan Institute of Medical Research |
| Other ID(s) | WZTL002-2|U1111-1305-7917 |
| Cohort 1 | |||||||||||||
|
|||||||||||||